"Chia Tai Tianqing Biological: The 26-valent pneumococcal conjugate vaccine has launched Phase I clinical trials in Australia"

Chengdu Institute of Biological Products announced that the 26-valent pneumococcal conjugate vaccine independently developed by its wholly-owned subsidiary, Beijing Chengdu Green Bamboo Biopharmaceutical Co., Ltd., has started Phase I clinical trials in Australia. This vaccine is used to prevent invasive diseases caused by pneumococcal serotypes, covering the most common serotypes currently and providing broader coverage. Pneumococcus is the main pathogen causing acute respiratory infections in infants and elderly people. Global disease burden research shows that in 2021, this pathogen caused 97.9 million cases of illness and 500,000 deaths.